Jiyoung Lee
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (18)
Year:
2026
Year:
2026
BACH1 has been identified as a functional regulator of cancer metastasis and metabolic signaling in breast cancer cells. However, the clinical relevance of BACH1 expression in breast tumors remains poorly understood. Using a tissue microarray from a cohort of 130 patients, we assessed the expression of BACH1 and its known target gene, MCT1 (encoded by SLC16A1), through immunohistochemistry (IHC). The expression data were then analyzed in relation to clinical variables, including breast cancer subtypes, tissue types, tumor size and grade, patient racial background, and age group. We found positive associations between BACH1 expression and tumor size, tumor grade, and the basal-like subtype. Importantly, BACH1 expression was significantly higher in tumors from Black women compared to those from White women, as well as in the basal-like subtype of breast tumors from Black women. Additionally, a positive correlation was observed between BACH1 and MCT1 IHC scores in tumors from Black women, while a weak association was noted in tumors from White women. Our study provides compelling evidence that BACH1 expression is evident based on the race and subtypes of breast cancer patients.
Year:
2025
Prostaglandin regulation is known to play a pivotal role in tumorigenesis; however, the contributions of the prostaglandin-metabolizing enzyme 15-hydroxyprostaglandin dehydrogenase (HPGD) to cancer development remain poorly understood. In this study, we investigate the effects of HPGD on cell viability, proliferation, anchorage-independent growth, and migration in triple-negative breast cancer (TNBC), an aggressive subtype of breast cancer. Overexpression of HPGD in human TNBC cells resulted in both positive and negative regulation of cell proliferation and colony formation, with these effects occurring independent of prostaglandin E2 (PGE2). In contrast, overexpression of the mouse homolog, Hpgd, in murine TNBC cells led to a consistent but modest reduction in cell viability and colony formation, indicating that HPGD activity varies depending on species and cell line context. Notably, TNBC cells expressing a mutant form of Hpgd (Hpgdmut), which lacks the ability to bind PGE2, exhibited similar functional outcomes in cell viability and colony formation as those expressing wild-type Hpgd (HpgdWT). These findings suggest that HPGD may exert its tumorigenic effects through non-enzymatic mechanisms, potentially by involving modulation of KRAS signaling in human TNBC cells. Our results highlight the diverse roles of HPGD in cancer biology, particularly in the context of TNBC, and point to non-enzymatic pathways as a significant aspect of its tumorigenic activity.
Year:
2025
Background/Objectives: Resistant starch intake has been shown to influence gut microbiota composition and affect metabolic markers. These effects may be partially attributed to enhanced short-chain fatty acid (SCFA)-mediated energy harvesting and hepatic lipogenesis induced by resistant starch fermentation. However, there is a lack of prospective research addressing these associations. To address this gap, we performed a double-blind, randomized dietary intervention study to investigate the impact of high versus low resistant starch consumption on metabolic markers and gut microbiota among adult women presenting with risk factors for metabolic syndrome. Methods: A total of 30 participants were randomly assigned to either the low-resistant starch (LRS) or high-resistant starch (HRS) diet groups. Each group, comprising 15 participants, consumed one food product per day enriched with either high or low resistant starch for 8 weeks. Changes in metabolic indices and gut microbiota were assessed and compared with baseline values, as assessed before diet (Week 0). Results: After 8 weeks of intervention, the HRS diet significantly increased body weight, body fat, and triglyceride (TG) level (mean change ≈ +40 mg/dL), while reducing blood pressure. Analysis of intestinal microbiota in the HRS group revealed a statistically significant increase in the genus Veillonella following the intervention. Conversely, the genus Marvinbryantia increased significantly in the LRS group. Conclusions: In women with metabolic risk factors, resistant starch supplementation elicited mixed metabolic responses—showing a modest reduction in blood pressure but concurrent increases in adiposity and TG concentrations. As the TG elevation reached a clinically meaningful magnitude, dietary interventions involving high-resistant starch should incorporate regular lipid monitoring to ensure cardiometabolic safety. Collectively, these findings highlight the complex interplay between SCFA-producing gut microbiota and host energy metabolism, suggesting that individualized dietary strategies may be required to optimize metabolic outcomes.
Year:
2025
Dysregulated insulin signaling reduces HNSCC tumor growth. A, Plasma insulin concentration of vehicle- or STZ-treated mice (40 mg/kg i.p. for 5 consecutive days; n = 4 for each group). Two-tailed t test. *, P B, Representative H&E staining of pancreatic tissues collected from vehicle- or STZ-treated mice. Dashed lines denote individual pancreatic islets. Scale bars, 1 mm. C, Intraperitoneal glucose tolerance test of vehicle- and STZ-treated mice ( n = 4 for each group). D, In vivo tumor growth of FaDu xenograft tumors in vehicle-treated ( n = 4) and STZ-treated ( n = 4) mice. Two-way ANOVA. ****, P E, H&E and IHC analyses of pH2A.X, 4HNE, and Ki67 in FaDu xenograft tumors collected from vehicle- and STZ-treated mice. Scale bars, 1 mm. F, IHC analysis quantification of % area of 4HNE (lipid peroxidation marker), pH2A.X (DNA damage marker), and Ki67 (nuclear/cell proliferation marker) in xenografted tumors. Four to six images of each tumor were captured and analyzed for quantification ( n = 4 for each group). Two-tailed t test, **, P P
Year:
2025
Auranofin induces cytotoxicity as a pro-oxidant in HNSCC. A and B, In vitro proliferation (top) and intracellular H 2 O 2 levels (bottom) of FaDu ( A ) or SCC-61 ( B ) cells treated with vehicle, WZB117 (20 μmol/L), auranofin (1 μmol/L), or combination of WZB117 and auranofin ( n = 6 for each group). Two-way ANOVA (top) or two-tailed t test (bottom). ****, P P P C–F, In vivo tumor growth ( C ), tumor weights ( D ), images of individual tumors ( E ), and IHC analysis of GLUT1, pH2A.X, 4HNE, and CC3 ( F ) in SCC-61 xenograft tumors treated with vehicle PBS/DMSO ( n = 6) or auranofin (10 mg/kg i.p. daily; n = 6). Two-way ANOVA for tumor growth ( C ) and two-tailed t test for tumor weight ( D ). ****, P P G, IHC analysis quantification of % area of 4HNE (lipid peroxidation marker), pH2A.X (DNA damage marker), and CC3 (apoptotic cell marker) in xenografted tumors ( n = 6 for each group). Four to six images of each tumor were captured and analyzed for quantification. Two-tailed t test. **, P H, In vivo tumor growth of FaDu xenograft tumors treated with vehicle PBS/DMSO ( n = 16), WZB117 (20 mg/kg i.p. daily; n = 16), auranofin (10 mg/kg i.p. daily; n = 15), or combination of WZB117 and auranofin ( n = 12). Two-way ANOVA. ****, P P P I, In vivo tumor growth of SCC-61 xenograft tumors treated with vehicle PBS/DMSO ( n = 6), WZB117 (20 mg/kg i.p. daily; n = 7), auranofin (10 mg/kg i.p. daily; n = 7), or combination of WZB117 and auranofin ( n = 7). Two-way ANOVA. ****, P P P
Year:
2025
GLUT1 ablation attenuates tumorigenesis in 4NQO-induced mouse model of human HNSCC. A, Schematic showing timeline for treatment of mice with 4NQO. 4NQO was administered in drinking water for 8 weeks and replaced with normal drinking water for the remainder of the study. Tongues were collected every 2 weeks after the first exposure to 4NQO for analyses. For Cre-mediated GLUT1 ablation in basal epithelial cells, tamoxifen was injected (100 mg/kg i.p. daily for 5 consecutive days) 4 weeks after the final administration of 4NQO. Tumors were harvested 4 weeks after the final tamoxifen injection. B, Representative IHC analyses of GLUT1 expression in CK5 + and p63 + basal epithelial cells of untreated and 4NQO-treated mice. C, Representative images of tumor-bearing tongues from 4NQO-treated mice; black arrowheads depict squamous tongue tumors (left). Graph shows quantification of the number of visible tongue tumors identified in 4NQO-treated WT and Krt5 + basal epithelial–specific GLUT1 CKO mice ( n = 6 for each group). Mann–Whitney U test. P = 0.06 (right). D, Representative H&E images of 4NQO-treated WT and CKO mouse tongues. Arrows depict 4NQO-induced squamous tumors (left). Graph shows quantification of 4NQO-induced tongue tumor area (μm 2 ) in GLUT1 WT and CKO mice ( n = 6 for each group). Mann–Whitney U test. **, P E, Representative co-immunofluorescent staining of GLUT1 and p63 in 4NQO-induced squamous tongue tumors of GLUT1 WT and GLUT1 CKO mice. DAPI, 4',6-diamidino-2-phenylindole. F, Representative IHC analyses of p63, GLUT1, and Ki67 expression in 4NQO-induced squamous tongue tumors. All error bars represent mean ± SEM. All scale bars, 1 mm unless otherwise noted. H&E, hematoxylin and eosin; KO, knockout.
Year:
2025
Head and neck squamous cell carcinoma (HNSCC) remains a clinically challenging malignancy with limited targeted therapy options and poor patient outcomes. Thus, identifying unique dependencies, including HNSCC-specific metabolic reprogramming, is imperative for improving treatment strategies for this disease. In this study, we show that HNSCC relies on elevated glucose transporter 1 (GLUT1)–mediated glucose uptake to support redox homeostasis and tumor growth. Analyses of GLUT1 expression data in tumors and cancer cell lines reveal significant upregulation of GLUT1 in HNSCC relative to both normal tissue and other cancer subtypes and that high GLUT1 expression correlates with poorer clinical outcomes. Using a basal epithelial layer–specific GLUT1-knockout mouse model, we demonstrate that GLUT1 ablation in HNSCC cells of origin markedly attenuates tumor initiation and progression, implicating the necessity of GLUT1 in HNSCC tumorigenesis. Building on this observation, combining pharmacologic inhibition of GLUT1 with pro-oxidants such as vitamin C and auranofin induces potent cytotoxicity in vitro and in vivo , partly by precipitating oxidative stress. We further observe that insulin signaling is required to sustain glucose uptake and redox homeostasis, as insulin receptor knockdown decreases proliferation and increases reactive oxygen species levels. Together, these results suggest that although GLUT1 overexpression is a key driver of glucose uptake, insulin signaling also contributes to the metabolic and oncogenic pathways underlying HNSCC progression. Consequently, strategies that co-target GLUT1 and insulin signaling to restrict glucose flux may synergize with pro-oxidant therapies, offering a promising therapeutic avenue for HNSCC. Significance: Enhanced GLUT1 expression and oncogenic insulin signaling drive elevated glucose uptake in HNSCC, which contribute to the maintenance of redox homeostasis and tumor growth. Disrupting both glucose uptake and redox balance may offer a promising therapeutic approach.
Year:
2025
Insulin signaling promotes glucose-mediated antioxidative capacities in HNSCC. A, In vitro proliferation of FaDu cells in 25 mmol/L glucose media treated with or without 5 ng/mL insulin ( n = 4 for each group). Two-way ANOVA. ****, P B, Immunoblot analysis of pAKT and total AKT expression in FaDu cells treated with 20 ng/mL insulin over a time period of 0–120 minutes. C and D, Relative glucose uptake ( C ) and intracellular ROS measurement ( D ) in FaDu cells treated with 20 ng/mL insulin in 25 or 5 mmol/L glucose conditions ( n = 3 for each group). Two-tailed t test. ****, P P P E, In vitro proliferation of shScr, shINSR, or shINSR + 5 mmol/L NAC FaDu cells ( n = 4 for each group). Two-way ANOVA. **, P F, Immunoblot analyses of shScr and shINSR FaDu cells. β-Actin was used as the loading control. G and H, Relative glucose uptake ( G ) and intracellular ROS levels ( H ) in shScr and shINSR FaDu cells ( n = 3). Two-tailed t test. ****, P P I and J, In vitro proliferation of shScr, oncogenic mutant AKT E17K and PIK3CA H1047L expressing FaDu cells grown in 5 or 25 mmol/L glucose media ( n = 4 for each group). Two-way ANOVA. ****, P K, Immunoblot analysis of pAKT, AKT, pS6, S6, p4EBP1, and 4EBP1 expression in shScr and mutant AKT E17K and PIK3CA H1047L FaDu cells. L, Relative cellular glucose uptake and intracellular H 2 O 2 levels in FaDu PIK3CA H1047L mutant cells cultured in 5 or 25 mmol/L glucose ( n = 3 for each group). Two-tailed t test. ***, P M, Relative cellular glucose uptake and intracellular H 2 O 2 levels in FaDu AKT E17K mutant cells cultured in 5 or 25 mmol/L glucose ( n = 3 for each group). Two-tailed t test. *, P
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Collaborators (13)
Tae Gyu Oh
Assistant Professor
University of Oklahoma Health Sciences Center
Junho Hur
Associate Professor
Hanyang University
Jung-whan Kim
Associate Professor
University of Oklahoma
Pankaj Singh
Professor and Chair
University of Oklahoma Health Sciences Center
Chul‐Ho Kim
Ajou University
N. Maritza Dowling
Professor, Biostatistics & Measurement
George Washington University
Dinesh Thotala
Associate Professor
University of Oklahoma Health Sciences Center
Nam-Seok Joo
Ajou University School of Medicine
Hoon Hur
Professor
Ajou University
Seong-Ho Park
Hanyang University
Kyu-Nam Kim
Ajou University School of Medicine
Tae Hoon Kim
Professor
University of Texas at Dallas
Ji Yun Jeong
Sungkyunkwan University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.